UNSPSC 51181628: Protirelin tartrate

This classification denotes a hypothalmic hormone with the molecular structure C16H22N6O4.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, SYW8T997EQ chemically known as l-prolinamide, 5-oxo-l-prolyl-l-histidyl-, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more commonly known as protirelin tartrate, which bears US NIH Compound Identifier 176174. European Medicines Agency schedules Protirelin tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04112MIG.

Most nations, for tariff and trade purposes, schedule protirelin tartrate under HS 29371900. As of Q4 2014, PROTIRELIN TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C1C([NH]CN1)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N)NC(=O)[C@@H]3CCC(=O)N3.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51181628 Protirelin tartrate is a Commodity code covering a specific pharmaceutical active ingredient and its formulations. State and local governments procure protirelin tartrate and other generic pharmaceuticals through cooperative purchasing vehicles to supply correctional facilities, public health clinics, state hospitals, and other institutional care settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and distributors of generic multi-source pharmaceuticals and over-the-counter products under this code. Solicitation activity centers on establishing framework agreements with multiple vendors to supply products through authorized pharmaceutical wholesalers, with vendors required to maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, contractual relationships with at least two of three specified wholesalers, and comprehensive insurance including $5 million commercial general liability coverage. Buyers evaluate submissions primarily on price competitiveness (75 percent weighting), with secondary criteria including fixed pricing stability, administrative fee compliance, and electronic data interchange capability.

MMCAP's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, represents the most recent documented solicitation activity under this code. The opportunity encompasses participating state and local government facilities across Minnesota and Oregon. Awarded vendors will supply products to member agencies through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contract effectiveness targeted for July 1, 2026. The procurement structure allows MMCAP to make sole awards, dual awards, or multi-awards based on therapeutic considerations and patient safety. Vendors must submit detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations in CSV format through the ePro procurement system, with products required to be available in the marketplace by May 15, 2026 and maintain minimum six-month shelf life with expiration dates at least one year from manufacture.